In a recent conversation, Dr. Houman Hemmati (ophthalmologist, clinical trialist, and biotech innovator) didn’t hold back in describing the systemic inefficiencies he sees every day. From sponsor overreach to CRO micromanagement to administrative overload at research sites, the entire model is built to sustain activity, not outcomes.

He believes that AI can eliminate a lot of the operational drag that wastes time and wears people down. And he predicted a lot of the AI-centric changes that have been announced by the FDA recently.